You just read:

Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial

News provided by

Array BioPharma Inc.

Feb 06, 2018, 08:00 ET